



## Modulating CD4+ T Cells for Cancer Immunotherapy: Emerging Strategies and Applications

Guest Editor:

**Prof. Dr. Haval Shirwan**

School of Medicine, University of  
Missouri, Columbia, MO, USA

Deadline for manuscript  
submissions:

**31 July 2024**

### Message from the Guest Editor

Dear colleagues,

Immunomodulation is one of the key strategies used to fight cancer. As CD4+ T cells are key in regulating various effector immune responses, modulating their function to generate a robust effector response while overcoming the immunosuppressive tumor microenvironment is paramount for effective cancer immunotherapy. CD4+ T cells may promote antitumor immunity via different mechanisms, such as enhancing antigen presentation; the costimulation, activation, and homing of effector immune cells to the tumor site; and the direct killing of cancer cells. Several cancer vaccine approaches targeting CD4+ T cells have shown promise in the clinic. Harnessing the full potential of the immune system to fight cancer still requires a deeper understanding of CD4+ T cell activation, acquisition of the effector function, and sustaining a durable and robust antitumor immune response.

In this Special Issue, we invite scholars to submit their work focusing on the role of CD4+ T cells in cancer immunotherapy and the design of immunomodulatory strategies, including vaccines, to regulate these cells for robust therapeutic immune response against cancer.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

## Contact Us

---

Vaccines Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)